Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
46 hedge funds and large institutions have $4.55M invested in Accelerate Diagnostics in 2024 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 6 closing their positions.
900% more call options, than puts
Call options by funds: $20K | Put options by funds: $2K
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
7% more funds holding
Funds holding: 43 → 46 (+3)
53% less capital invested
Capital invested by funds: $9.78M → $4.55M (-$5.23M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.92M |
| 2 |
GAM
Griffin Asset Management
New York
|
+$212K |
| 3 |
CS
Cannell & Spears
New York
|
+$181K |
| 4 |
BC
Birchview Capital
Burlington,
Vermont
|
+$158K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$127K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Chartist Inc
Seal Beach,
California
|
-$270K |
| 2 |
CIA
Cladis Investment Advisory
Billings,
Montana
|
-$124K |
| 3 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$110K |
| 4 |
SIMG
Sonora Investment Management Group
Tucson,
Arizona
|
-$70.6K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$60.5K |
AXDX Hedge Fund Activity: Q1 2024 in Review
46 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q1 2024, worth a combined $4.55M — down 53% from $9.78M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new AXDX positions and 6 closed out — a net gain of 6 holders — while 10 added to existing stakes and 8 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.92M. The largest seller was Chartist Inc, exiting entirely with an estimated $270K sold.
- 46 institutional investors held Accelerate Diagnostics (AXDX) as of Q1 2024, up from 43 in Q4 2023.
- Funds reported $4.55M of Accelerate Diagnostics stock for Q1 2024, down 53% quarter-over-quarter.
- 12 funds opened new Accelerate Diagnostics positions in Q1 2024 and 6 closed out, a net change of +6 holders.
- The largest Accelerate Diagnostics buyer in Q1 2024 was Armistice Capital, an estimated $2.92M added.
- The largest Accelerate Diagnostics seller in Q1 2024 was Chartist Inc, an estimated $270K sold.
Based on aggregated 13F filings for Q1 2024.